| 日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
| 2025/03/11 | 05 : 30 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/12/20 | 22 : 00 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/12/20 | 22 : 00 | GlobeNewswire Inc. | Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/10/05 | 05 : 01 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/10/05 | 05 : 01 | GlobeNewswire Inc. | Altamira Therapeutics Provides Update on Nasdaq Listing | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/09/27 | 22 : 01 | GlobeNewswire Inc. | Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/09/24 | 21 : 15 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/09/24 | 21 : 01 | GlobeNewswire Inc. | Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/09/20 | 22 : 01 | GlobeNewswire Inc. | Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/09/20 | 05 : 17 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/09/20 | 05 : 01 | GlobeNewswire Inc. | Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/09/19 | 05 : 19 | Edgar (US Regulatory) | Form 424B4 - Prospectus [Rule 424(b)(4)] | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/09/18 | 13 : 15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/09/18 | 06 : 00 | GlobeNewswire Inc. | Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/09/17 | 02 : 55 | Edgar (US Regulatory) | Form F-1/A - Registration statement for certain foreign private issuers: [Amend] | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/09/16 | 22 : 29 | Edgar (US Regulatory) | Form F-1/A - Registration statement for certain foreign private issuers: [Amend] | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/09/16 | 21 : 30 | GlobeNewswire Inc. | Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/09/03 | 22 : 01 | GlobeNewswire Inc. | Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11 | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/08/23 | 22 : 01 | GlobeNewswire Inc. | Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/08/23 | 05 : 53 | Edgar (US Regulatory) | Form F-1 - Registration statement for certain foreign private issuers | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/08/16 | 22 : 01 | GlobeNewswire Inc. | Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/08/12 | 22 : 02 | GlobeNewswire Inc. | Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/07/19 | 22 : 01 | GlobeNewswire Inc. | Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/07/15 | 13 : 15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/07/09 | 06 : 17 | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/06/20 | 22 : 01 | GlobeNewswire Inc. | Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/05/28 | 23 : 31 | GlobeNewswire Inc. | Altamira Therapeutics Provides Business Update | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/05/23 | 21 : 47 | GlobeNewswire Inc. | Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/05/17 | 05 : 15 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:CYTO | Altamira Therapeutics Ltd |
| 2024/05/01 | 21 : 47 | GlobeNewswire Inc. | Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation | NASDAQ:CYTO | Altamira Therapeutics Ltd |
